LWM Advisory Services LLC Acquires 43 Shares of Eli Lilly and Company (NYSE:LLY)

LWM Advisory Services LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,844 shares of the company’s stock after acquiring an additional 43 shares during the period. Eli Lilly and Company comprises approximately 1.0% of LWM Advisory Services LLC’s holdings, making the stock its 22nd largest holding. LWM Advisory Services LLC’s holdings in Eli Lilly and Company were worth $1,424,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of LLY. AMF Tjanstepension AB lifted its holdings in Eli Lilly and Company by 113.7% during the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after buying an additional 176,552 shares in the last quarter. Values Added Financial LLC lifted its holdings in Eli Lilly and Company by 4.9% during the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after buying an additional 17 shares in the last quarter. Global Trust Asset Management LLC lifted its holdings in Eli Lilly and Company by 66.5% during the 3rd quarter. Global Trust Asset Management LLC now owns 1,668 shares of the company’s stock worth $1,478,000 after buying an additional 666 shares in the last quarter. HT Partners LLC lifted its holdings in Eli Lilly and Company by 0.4% during the 3rd quarter. HT Partners LLC now owns 4,256 shares of the company’s stock worth $3,771,000 after buying an additional 18 shares in the last quarter. Finally, DT Investment Partners LLC lifted its holdings in Eli Lilly and Company by 11.2% during the 3rd quarter. DT Investment Partners LLC now owns 745 shares of the company’s stock worth $660,000 after buying an additional 75 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Finally, Barclays cut their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,000.28.

Eli Lilly and Company Price Performance

LLY stock opened at $874.12 on Friday. The stock has a 50-day moving average price of $801.33 and a two-hundred day moving average price of $847.13. The stock has a market cap of $828.82 billion, a PE ratio of 74.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is 51.24%.

Eli Lilly and Company declared that its board has initiated a share buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.